Refractory Dyspnea in a Patient with End-Stage Idiopathic Pulmonary Fibrosis (Palliative Care unit Case Study)

Treating dyspnea in patients with idiopathic pulmonary fibrosis is a challenge. The foreign experience of using low doses of opioids to relieve dyspnea in patients with progressing diseases is controversial among Russian specialists. The presented clinical case is an 83-year-old patient with idiopathic pulmonary fibrosis in the terminal stage and refractory dyspnea, progressive respiratory failure of II - III degrees, and concomitant exertional angina II FC and organic anxiety disorder. The patient was offered low-dose morphine injections (2 mg 5 times a day subcutaneously) to relieve the shortness of breath. The patient, who had not previously received opioids, and his relatives gave prior consent to the use of morphine. Within a week from the moment of hospitalization, the general and psycho-emotional state of the patient improved, dyspnea decreased, and night sleep was partially normalized. However, а week later, being in a severe but relatively stable condition, the patient died from a massive nosebleed. Shown, that the traditional approach to reducing dyspnea and the associated agitation in patients with interstitial lung disease is the use of corticosteroids and psychotropic therapeutics in increasing doses. The use of low doses of opioids to relieve dyspnea in patients with non-cancer disease meets many organizational, medical, and psychological barriers. At the same time, this therapy is recognized as successful and safe in the foreign palliative practice. Overcoming the existing barriers based on the evidence from clinical trials, as well as the domestic and foreign clinical practice of the safe use of low doses of opioids would expand the arsenal of effective treatments for refractory dyspnea.

1. Russian Respiratory Society. [Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: Federal Clinical Guidelines]. Moscow; 2016. Available at: https://spulmo.ru/download/IPFrec.pdf (in Russian).

2. Lederer D.J., Martinez F.J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2018; 378 (19): 1811-1823. DOI: 10.1056/nejmra1705751.

3. Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-2011. Lancet Respir. Med. 2014; 2 (7): 566-572. DOI: 10.1016/s2213-2600(14)70101-8.

4. Strongman H., Kausar I., Maher T.M. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv. Ther. 2018; 35 (5): 724-736. DOI: 10.1007/s12325-018-0693-1.

5. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237. DOI: 10.1186/s12916-015-0495-0.

6. Tang Y.W., Johnson J.E., Browning P.J. et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 2003; 41 (6): 2633-2640. DOI: 10.1128/jcm.41.6.2633-2640.2003.

7. Manika K., Alexiou-Daniel S., Papakosta D. et al. A. Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2007; 24 (2): 134-140.

8. Kelly B.G., Lok S.S., Hasleton P.S. et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166 (4): 510-513. DOI: 10.1164/rccm.2103058.

9. Kropski J.A., Lawson W.E., Blackwell T.S. Right place, right time: the evolving role of herpesvirus infection as a “second hit” in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 302 (5): L441-444. DOI: 10.1152/ajplung.00335.2011.

10. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157 (1): 199-203. DOI: 10.1164/ajrccm.157.1.9704130.

11. Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156 (10): 684-691. DOI: 10.7326/0003-4819-156-10-201205150-00004.

12. Homma S., Bando M., Azuma A. et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir. Investig. 2018; 56 (4): 268-291. DOI: 10.1016/j.resinv.2018.03.003.

13. Martinez F.J., Safrin S., Weycker D. et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005; 142 (12, Pt 1): 963-967. DOI: 10.7326/0003-4819-142-12_part_1-200506210-00005.

14. King T.E. Jr, Albera C., Bradford W.Z. et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am. J. Respir. Crit. Care Med. 2014; 189 (7): 825-831. DOI: 10.1164/rccm.201311-1951OC.

15. Rozenberg D., Sitzer N., Porter S. et al. Idiopathic pulmonary fibrosis: A review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life. J. Pain. Symptom. Manage. 2020; 59 (6): 1362-1378. DOI: 10.1016/j.jpainsym-man.2019.12.364.

16. Webb M., Moody L.E., Mason L.A. Dyspnoea assessment and management in hospice patients with pulmonary disorders. Am. J. Hosp. Palliat. Care. 2000; 17 (4): 259-264. DOI: 10.1177/104990910001700412.

17. Ripamonti C. Management of dyspnea in advanced cancer patients. Support. Cancer Care. 1999; 7: 233-243. DOI: 10.1007/s005200050255.

18. Allen S., Raut S., Woollard J., Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliative Med. 2005; 19 (2): 128-130. DOI: 10.1191/0269216305pm998oa.

19. Lanken P.N., Terry P.B., DeLisser H.M. et al. An official American Thoracic Society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses. Am. J. Respir. Crit. Care Med. 2008; 177 (8): 912-927. DOI: 10.1164/rccm.200605-587ST.

20. Muers M.F. Opioids for dyspnoea. Thorax. 2002; 57 (11): 922-923. DOI: 10.1136/thorax.57.11.922.

21. Twycross R., Wilcock A., eds. Introducing Palliative Care. 5th Edn. Palliativedrugs.com Ltd; 2016.

22. Jennings A.L., Davies A.N., Higgins J.P.T. et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57 (11): 939-944. DOI: 10.1136/thorax.57.11.939.

23. SIGN. Management of chronic pain (SIGN 136). Edinburgh: SIGN; 2013. Available at: http://www.sign.ac.uk [Accessed: December, 2013].

24. Trivedi M., Shaikh S., Gwinnut C. Pharmacology of Opioids. Update in Anaesthesia. Originally published in Anaesthesia Tutorial of the Week; 2007: 118-124. Available at: http://e-safe-anaesthesia.org/e_library/03/Opioid_pharmacology_Update_2008.pdf

25. Parshall M.B., Schwartzstein R.M., Adams L. et al. An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 2012; 185 (4): 435-452. DOI: 10.1164/rccm.201111-2042ST.

26. Mahler D.A., Selecky P.A., Harrod C.G. et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010; 137 (3): 674-691. DOI: 10.1378/chest.09-1543.

27. Boscarino J.A., Rukstalis M., Hoffman S.N. et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction. 2010; 105 (10): 1776-1782. DOI: 10.1111/j.1360-0443.2010.03052.x.

28. Arthur J., Edwards T., Reddy S. et al. Outcomes of a specialized interdisciplinary approach for patients with cancer with aberrant opioid-related behavior. Oncologist. 2018; 23 (2): 263-270. DOI: 10.1634/theoncologist.2017-0248.